Analyst Viewpoint
The mounting global cancer burden is a key factor fueling the cancer supportive care drugs market size. The demand for supportive care drugs intensifies as cancer cases escalate.
G-CSFs, ESAs, antiemetics, bisphosphonates, opioids, NSAIDs, and topical treatments play crucial roles in managing the multifaceted challenges of cancer care. The cancer supportive care drugs market caters to diverse cancer indications, including lung, breast, prostate, liver, bladder, leukemia, ovary, and melanoma.
Distribution channels, encompassing hospital pharmacies, retail pharmacies, and compounding pharmacies, further contribute to market development. The cancer supportive care drugs market has a major role in addressing the evolving needs of cancer patients, bridging critical gaps in comprehensive and personalized cancer care solutions.
Cancer supportive care drugs refer to a category of medications designed to alleviate the side effects and symptoms associated with cancer and its treatments. These drugs aim to enhance the overall quality of life for individuals undergoing cancer therapy by managing and mitigating the adverse effects of treatments such as chemotherapy, radiation therapy, and surgery.
Cancer supportive care drugs are diverse and target specific issues commonly experienced by cancer patients, including pain, nausea, anemia, immune system suppression, bone complications, and more. The surge in cancer prevalence, as reported by various health organizations, underscores the urgency to address the multifaceted challenges faced by cancer patients.
Retail pharmacies play a crucial role in the distribution of cancer supportive care drugs. The accessibility and convenience offered by retail pharmacies is important in driving patient engagement and adherence to supportive care regimens.
The escalating global incidence of cancer is a key driver propelling the cancer supportive care drugs market demand. The relentless rise in cancer cases worldwide leads to an imperative need for effective management of treatment-related side effects and an enhancement of overall patient well-being.
In 2021, the American Cancer Society reported 1.9 million new cases and 608,570 deaths in the U.S., with projections maintaining a similar trend in 2022. WHO identified cancer as the primary cause of nearly 10 million deaths in 2020.
This driver reflects the growing recognition within the healthcare community of the vital role that supportive care drugs play in mitigating the adverse effects of cancer treatments.
As the number of cancer diagnoses continues to increase, the pharmaceutical industry is encouraged to innovate and develop advanced supportive care solutions, ensuring that patients receive comprehensive care to improve treatment experiences and outcomes.
Furthermore, various research studies, such as the one published in February 2021 titled "Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention," contribute valuable insights.
The study highlights the growing evidence supporting the beneficial role of non-steroidal anti-inflammatory drugs (NSAIDs) in colorectal cancer chemoprevention, emphasizing the continuous exploration of innovative approaches in cancer care.
Advancements in cancer therapeutics and continual launch of new drugs by key players is expected to offer lucrative opportunities for market expansion. In September 2021, Intas Pharmaceuticals introduced Oral Azacitidine in India, branded as Azadine-O, specifically for acute myeloid leukemia.
The drug's approval for use in maintenance therapy for adult patients with acute myeloid leukemia enhances its accessibility, contributing to market growth.
Similarly, approval of the breast cancer drug NERLYNX (neratinib) by the National Pharmaceutical Regulatory Authority in Malaysia in July 2020 further emphasizes the positive trajectory.
NERLYNX has demonstrated efficacy in reducing the risk of cancer recurrence, particularly in women with breast cancer who have undergone surgery, chemotherapy, and prior trastuzumab-based therapy.
These launches signify a continuous commitment to advancing cancer care, fostering growth prospects for the cancer supportive care drugs industry during the forecast period.
In the cancer supportive care drugs market segmentation based on drug class, G-CSFs (Granulocyte Colony-Stimulating Factor) held the largest share in 2022, signifying a substantial preference and utilization of G-CSFs in the management of cancer-related complications and treatment side effects.
G-CSFs play a crucial role in stimulating the production of white blood cells, mitigating the risk of infections, and supporting patients undergoing intensive chemotherapy. The dominance of G-CSFs reflects their effectiveness in addressing a critical aspect of cancer care – the maintenance of a healthy immune system during aggressive treatment regimens.
As chemotherapy often suppresses the bone marrow, leading to a decline in white blood cell count, G-CSFs are integral in preventing infections and ensuring patients can continue and complete their treatment.
As per the cancer supportive care drugs market analysis, in 2022, the breast cancer segment asserting its dominance and secured the largest market share, based on indication.
The American Cancer Society's estimates for breast cancer in the United States for 2024 further underscore the urgency of addressing this health concern. The projections indicate that approximately 310,720 new cases of invasive breast cancer are likely to be diagnosed in women, along with about 56,500 new cases of ductal carcinoma in situ (DCIS).
These statistics emphasize the critical role of supportive care drugs in the overall management and care of individuals affected by breast cancer.
According to the latest cancer supportive care drugs market forecast, North America is poised for substantial growth, and is expected to secure a major share in the global landscape. Surge in prevalence of cancer and robust initiatives by both public and private entities is driving the market dynamics in the region.
The United States and Canada, with well-developed healthcare systems, allocate significant resources for oncology research and treatment, making them attractive markets for various industry players. The considerable investment in research and development is an important market catalyst in the region.
The Asia Pacific cancer supportive care drugs market is experiencing notable growth. Rise in prevalence of cancer, increase in healthcare initiatives, and expansion of research and development activities are boosting market statistics in the region.
Asia Pacific is witnessing heightened demand for supportive care drugs due to growth in emphasis on comprehensive cancer care. Countries in Asia Pacific are investing in healthcare infrastructure and oncology research, attracting market players to address the evolving needs of cancer patients.
This dynamic environment, coupled with ongoing innovations in cancer therapeutics, positions Asia Pacific as a significant contributor to the global market value.
The global cancer supportive care drugs market is fragmented, with the presence of large number of players. Companies are focusing on investment in R&D and collaborations to increase their market share.
Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., and Helsinn Healthcare SA are the prominent cancer supportive care drugs market manufacturers.
Key players have been profiled in the cancer supportive care drugs market report based on parameters such as company overview, latest developments, business strategies, application portfolio, business segments, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 14.3 Bn |
| Market Forecast (Value) in 2031 | More than US$ 16.7 Bn |
| Growth Rate (CAGR) | 1.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 14.3 Bn in 2022
It is projected to reach more than US$ 16.7 Bn by the end of 2031
The CAGR is anticipated be 1.7% from 2023 to 2031
Escalating global incidence of cancer
Based on drug class, the G-CSFs (Granulocyte Colony-Stimulating Factor) segment accounted for more than 40% share in 2022
North America is expected to account for largest share from 2023 to 2031
Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., and Helsinn Healthcare SA.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Supportive Care Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution/ Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Drug Class/Brand Analysis
5.2. Top 3 Players Operating in the Market Space
5.3. Disease Prevalence and Incidence
5.4. COVID Impact Analysis
6. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Class, 2017-2031
6.3.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
6.3.2. ESAs (Erythropoiesis Stimulating Agent)
6.3.3. Antiemetics
6.3.4. Bisphosphonates
6.3.5. Opioids
6.3.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
6.3.7. Others (Topicals, etc.)
6.4. Market Attractiveness By Drug Class
7. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2017-2031
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Prostate Cancer
7.3.4. Liver Cancer
7.3.5. Bladder Cancer
7.3.6. Leukemia
7.3.7. Others (Ovarian Cancer, Melanoma, etc.)
7.4. Market Attractiveness By Indication
8. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others (Compounding Pharmacies, etc.)
8.4. Market Attractiveness By Distribution Channel
9. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Cancer Supportive Care Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Class, 2017-2031
10.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
10.2.2. ESAs (Erythropoiesis Stimulating Agent)
10.2.3. Antiemetics
10.2.4. Bisphosphonates
10.2.5. Opioids
10.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
10.2.7. Others (Topicals, etc.)
10.3. Market Value Forecast By Indication, 2017-2031
10.3.1. Lung Cancer
10.3.2. Breast Cancer
10.3.3. Prostate Cancer
10.3.4. Liver Cancer
10.3.5. Bladder Cancer
10.3.6. Leukemia
10.3.7. Others (Ovarian Cancer, Melanoma, etc.)
10.4. Market Value Forecast By Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others (Compounding Pharmacies, etc.)
10.5. Market Value Forecast By Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Cancer Supportive Care Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class, 2017-2031
11.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
11.2.2. ESAs (Erythropoiesis Stimulating Agent)
11.2.3. Antiemetics
11.2.4. Bisphosphonates
11.2.5. Opioids
11.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
11.2.7. Others (Topicals, etc.)
11.3. Market Value Forecast By Indication, 2017-2031
11.3.1. Lung Cancer
11.3.2. Breast Cancer
11.3.3. Prostate Cancer
11.3.4. Liver Cancer
11.3.5. Bladder Cancer
11.3.6. Leukemia
11.3.7. Others (Ovarian Cancer, Melanoma, etc.)
11.4. Market Value Forecast By Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others (Compounding Pharmacies, etc.)
11.5. Market Value Forecast By Country, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Cancer Supportive Care Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class, 2017-2031
12.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
12.2.2. ESAs (Erythropoiesis Stimulating Agent)
12.2.3. Antiemetics
12.2.4. Bisphosphonates
12.2.5. Opioids
12.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
12.2.7. Others (Topicals, etc.)
12.3. Market Value Forecast By Indication, 2017-2031
12.3.1. Lung Cancer
12.3.2. Breast Cancer
12.3.3. Prostate Cancer
12.3.4. Liver Cancer
12.3.5. Bladder Cancer
12.3.6. Leukemia
12.3.7. Others (Ovarian Cancer, Melanoma, etc.)
12.4. Market Value Forecast By Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others (Compounding Pharmacies, etc.)
12.5. Market Value Forecast By Country, 2017-2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Cancer Supportive Care Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2017-2031
13.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
13.2.2. ESAs (Erythropoiesis Stimulating Agent)
13.2.3. Antiemetics
13.2.4. Bisphosphonates
13.2.5. Opioids
13.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
13.2.7. Others (Topicals, etc.)
13.3. Market Value Forecast By Indication, 2017-2031
13.3.1. Lung Cancer
13.3.2. Breast Cancer
13.3.3. Prostate Cancer
13.3.4. Liver Cancer
13.3.5. Bladder Cancer
13.3.6. Leukemia
13.3.7. Others (Ovarian Cancer, Melanoma, etc.)
13.4. Market Value Forecast By Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others (Compounding Pharmacies, etc.)
13.5. Market Value Forecast By Country, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Cancer Supportive Care Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2017-2031
14.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
14.2.2. ESAs (Erythropoiesis Stimulating Agent)
14.2.3. Antiemetics
14.2.4. Bisphosphonates
14.2.5. Opioids
14.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
14.2.7. Others (Topicals, etc.)
14.3. Market Value Forecast By Indication, 2017-2031
14.3.1. Lung Cancer
14.3.2. Breast Cancer
14.3.3. Prostate Cancer
14.3.4. Liver Cancer
14.3.5. Bladder Cancer
14.3.6. Leukemia
14.3.7. Others (Ovarian Cancer, Melanoma, etc.)
14.4. Market Value Forecast By Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others (Compounding Pharmacies, etc.)
14.5. Market Value Forecast By Country, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Material Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Material Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Johnson & Johnson Services, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Material Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Heron Therapeutics, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Material Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Material Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. GSK plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Material Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Material Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Helsinn Healthcare SA
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Material Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
List of Tables
Table 01: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 02: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 03: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 06: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 07: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 08: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 09: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 10: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 11: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 12: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 13: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 14: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 15: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 18: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 19: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 20: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 21: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 22: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 23: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01: Global Cancer Supportive Care Drugs Market Size (US$ Mn) Forecast, 2017-2031
Figure 02: Global Cancer Supportive Care Drugs Market Value Share, by Drug Class (2022)
Figure 03: Global Cancer Supportive Care Drugs Market Value Share, by Indication (2022)
Figure 04: Global Cancer Supportive Care Drugs Market Value Share, by Distribution Channel (2022)
Figure 05: Global Cancer Supportive Care Drugs Market Value Share, by Region (2022)
Figure 06: Global Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
Figure 07 Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
Figure 08: Global Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
Figure 09: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 10: Global Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
Figure 11: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 12: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 13: Global Cancer Supportive Care Drugs Market Value Share, by Region, 2017-2031
Figure 14: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Region, 2017-2031
Figure 15: North America Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
Figure 16: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
Figure 17: North America Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
Figure 18: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 19: North America Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
Figure 20: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 21: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 22: North America Cancer Supportive Care Drugs Market Value Share, by Country, 2017-2031
Figure 23: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country, 2017-2031
Figure 24: Europe Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
Figure 25: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
Figure 26: Europe Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
Figure 27: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 28: Europe Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
Figure 29: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 30: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 31: Europe Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
Figure 32: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 33: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
Figure 34: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
Figure 35: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
Figure 36: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 37: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
Figure 38: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 39: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 40: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
Figure 41: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 42: Latin America Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
Figure 43: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
Figure 44: Latin America Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
Figure 45: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 46: Latin America Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
Figure 47: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 48: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 45: Latin America Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
Figure 50: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 51: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
Figure 52: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
Figure 53: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
Figure 54: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
Figure 55: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
Figure 56: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
Figure 57: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 58: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
Figure 59: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Supportive Care Drugs Market
*86 figures and 60 tables includes